Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial

Genitourinary Cancer

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

Lancet Oncol

Morgans AK, Haresh KP, Jievaltas M, Olmos D, Shore ND, Vjaters E, Xing N, Mohamed AF, Littleton N, Srinivasan S, Verholen F, Saad F

doi: 10.1016/S1470-2045(26)00014-8

Genitourinary Cancer

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

Eur Urol

Armstrong AJ, Petrylak DP, Shore ND, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Croitoru R, Wu R, Kalac M, Tang Y, Stenzl A, Azad AA

doi: 10.1016/j.eururo.2025.12.021

Genitourinary Cancer

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial

Eur J Cancer

Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, Aragon-Ching JB, Schostak M, Tutrone R, Morgans AK, Sentana-Lledo D, Joensuu H, Mohamed AF, Littleton N, Srinivasan S, Buttkewitz Y, Li R, Kuss I, Tombal B

doi: 10.1016/j.ejca.2026.116888

Genitourinary Cancer

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial

Eur J Cancer

Tombal B, Hussain M, Saad F, Fizazi K, Shore N, Kopyltsov E, Bögemann M, Mendez-Vidal MJ, Littleton N, Srinivasan S, Verholen F, Smith MR

doi: 10.1016/j.ejca.2026.116730

Genitourinary Cancer

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

Eur Urol

Riaz IB, Ahmed Naqvi SA, Faisal KS, He H, Rubab Khakwani KZ, Childs DS, Orme JJ, Ravi P, Singh P, Hussain SA, Chi K, Agarwal N, Merseburger AS, Davis ID, Armstrong A, Hussain MH, Smith M, Attard G, Tombal B, Fizazi K, James N, Omlin A, Gillessen S, Murad MH, Van Allen EM, Sweeney CJ, Bryce AH

doi: 10.1016/j.eururo.2025.09.007

Lung, Respiratory and Thoracic Cancer

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Lancet Oncol

Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, García Campelo R, Jotte R, Berz D, Spira A, Pérol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L

doi: 10.1016/S1470-2045(26)00282-2

Breast Cancer

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials

Lancet Oncol

Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M

doi: 10.1016/S1470-2045(26)00053-7

Genitourinary Cancer

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Prostate Cancer Prostatic Dis

Büttner T, Rizzo M, Bernal Vaca L, Molina-Cerrillo J, Alonso-Gordoa T, Juárez A, Buchler T, Seront E, Kucharz J, Gandur Quiroga MN, Bourlon MT, Bögemann M, Kopecky J, Rescigno P, Fiala O, Rodriguez-Vida A, Myint ZW, Ürün Y, Scagliarini S, Poprach A, Matthews D, Li H, Rizzo A, Mosca A, Lenci E, Melichar B, Wenzel M, Mandell P, Massari F, Antonarakis ES, Santoni M

doi: 10.1038/s41391-025-01067-3

Genitourinary Cancer

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study

Ann Oncol

Fizazi K, Clarke NW, De Santis M, Uemura H, Fay AP, Karadurmus N, Kwiatkowski M, Alvarez-Fernandez C, Jiang S, Sotelo M, Parslow D, Oliveira N, Kwon TG, Ye D, Boudewijns S, Danchaivijitr P, Rooney C, Gresty C, Yeste-Velasco M, Logan J, George DJ, CAPItello-281 Study Group

doi: 10.1016/j.annonc.2025.10.004

Related content

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials

Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 Phase III study